Australian and Kiwi startups in fields as diverse as cell therapy, wastewater treatment, and local government software raised ...

With help from the oversubscribed financing round, the Australian firm is eyeing early 2025 for a Phase I clinical trial of its TAG-72-targeting cell therapy.

Immunotherapy company Cartherics Pty Ltd. raised AU$15 million (US$10.3 million) in an oversubscribed series B round that will support the first clinical trial for lead chimeric antigen receptor ...

The latest funding will support the first clinical trial for CTH-401, the startup’s lead cell therapy product, to treat ovarian cancer.

A much-anticipated new treatment for ovarian cancer discovered in Melbourne is also being explored for other conditions ...

Melbourne-based biotechnology company Cartherics has raised $15 million to help advance its mission to rearm the body's ...

Cartherics Pty Ltd. has raised over its target of AU$15 million (US$10.3 million) in an oversubscribed private financing round. Funding will support a clinical trial for CTH-401, the company’s lead ...

Anticipating that thousands of team members are suffering severe impacts from Hurricane Helene, BayCare Health System has created a special relief fund to support staff in ...

Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and ...

Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the treatment of ...